PATH Influenza Vaccine Project: Accelerating the development of new influenza vaccines for low-resource countries

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 939-947

  Neuzil, Kathleen M ^a   Tsvetnitsky, Vadim ^a   Nyari, Linda J ^a   Bright, Rick A ^a,b   Boslego, John W ^a  

^a PATH   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

global access; Influenza Vaccine Project; influenza vaccines; low resource countries; pandemic influenza; PATH

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIVE VACCINE; SWINE INFLUENZA VACCINE;

DEVELOPING COUNTRY; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MEDICAL DECISION MAKING; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; VIRUS IMMUNITY; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERNATIONAL COOPERATION; PANDEMICS; POVERTY; SEASONS; VACCINATION; VACCINES, ATTENUATED; WORLD HEALTH;

EID: 84866721441     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.76     Document Type: Review

References (39)

1. Murray CJ, Lopez AD, Chin B et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 368(9554), 2211-2218 (2006).
2. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 301(10), 1066-1069 (2009).
3. Gooskens J, Jonges M, Claas EC, Meijer A, van den Broek PJ, Kroes AM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 301(10), 1042-1046 (2009).
4. Friede M, Palkonyay L, Alfonso C et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 29 (Suppl. 1), A2-A7 (2011).
5. Waltera EB, Rajagopala S, Zhub Y, et al. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine 28, 4376-4383 (2010).
6. Berkley JA, Munywoki P, Ngama M et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA 303(20), 2051-2057 (2010).
7. Brooks WA, Goswami D, Rahman M et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr. Infect. Dis. J. 29(3), 216-221 (2010).
8. Partridge J, Kieny MP; World Health Organization H1N1 influenza vaccine Task Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 28(30), 4709-4712 (2010).
9. Abelin A, Colegate T, Gardner S, Hehme N, Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 29(6), 1135-1138 (2011).
10. Perdue ML, Bright RA. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Vaccine 29 (Suppl. 1), A48-A50 (2011).
11. Skowronski DM, Janjua NZ, De Serres G et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342, c7297 (2011).
12. Wichmann O, Stocker P, Poggensee G et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill. 15(18), pii: 19561 (2010).
13. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580-589 (2007).
14. Wright PF. Vaccine preparedness-are we ready for the next influenza pandemic? N. Engl. J. Med. 358(24), 2540-2543 (2008).
15. Glezen WP. Cold-adapted, live attenuated influenza vaccine. Expert Rev. Vaccines 3(2), 131-139 (2004).
16. Rudenko L, van den Bosch H, Kiseleva I et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 29 (Suppl. 1), A40-A44 (2011).
17. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 30(5), 886-892 (2012).
18. Belshe RB, Edwards KM, Vesikari T et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007).
19. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685-696 (2007).
20. Update: novel influenza A (H1N1) virus infections-worldwide, May 6, 2009. MMWR Morb. Mortal Wkly Rep. 58(17), 453-458 (2009).
21. Dhere R, Yeolekar L, Kulkarni P et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 29 (Suppl. 1), A16-A21 (2011).
22. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343-1351 (2006).
23. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826-7834 (2011).
24. Landry N, Ward BJ, Trépanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010).
25. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin. Vaccine Immunol. 19(2), 128-139 (2012).
26. Dropulic B. Development of a human cell-based virus-like particle (VLP) vaccine for pandemic influenza. Presented at: 4th ESWI Conference, Malta, 11-14 September 2011.
27. Sambhara S, Poland GA. Breaking the immunogenicity barrier of bird flu vaccines. Lancet 370(9587), 544-545 (2007).
28. Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4(2), e4384 (2009).
29. Ferguson M, Risi G, Davis M et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J. Infect. Dis. 205(5), 733-744 (2012).
30. Stephenson I, Nicholson KG, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 359(15), 1631-1633 (2008).
31. Vesikari T, Knuf M, Wutzler P et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365(15), 1406-1416 (2011).
32. Uphoff H, An der Heiden M, Schweiger B et al. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009-a comparison of two methods; Germany, 2009/10. PLoS ONE 6(7), e19932 (2011).
33. Valenciano M, Kissling E, Cohen JM et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 8(1), e1000388 (2011).
34. Evers T, Bernard A, Fox CB et al. Simplified oil-in-waters emulsions for use with H5N1 pandemic influenza vaccines. Presented at: 4th ESWI Conference, Malta, 11-14 September 2011.
35. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
36. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012).
37. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 343, d5956 (2011).
38. Steel J, Lowen AC, Wang TT et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1(1), pii: e00018-10 (2010).
39. Bright RA, Neuzil KM, Pervikov Y, Palkonyay L. WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. Vaccine 27(45), 6366-6369 (2009).